Published: January 2021

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

Published: June 2018

Esta hoja informativa se puede usar como una guía para las personas que buscan tratamiento de salud mental. Ofrece tres pasos necesarios para llevar a cabo antes de utilizar un centro de tratamiento, así como las cinco señales de un centro de tratamiento de calidad, que incluye revisar la acreditación, la medicación, las prácticas basadas en la evidencia, el papel de las familias y las redes de apoyo.

Published: April 2018

This fact sheet serves as a guide for individuals seeking behavioral health treatment. It provides three necessary steps to complete prior to utilizing a treatment center and the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks.

Published: May 2013

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.

Published: May 2010

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.